- Home
- EWCZ vs CADL Comparison
EWCZ vs CADL Comparison
Compare EWCZ & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- CADL
- Stock Information
- Founded
- EWCZ 2004
- CADL 1999
- Country
- EWCZ United States
- CADL United States
- Employees
- EWCZ 203
- CADL N/A
- Industry
- EWCZ Package Goods/Cosmetics
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- CADL Health Care
- Exchange
- EWCZ Nasdaq
- CADL Nasdaq
- Market Cap
- EWCZ 239.2M
- CADL 250.0M
- IPO Year
- EWCZ 2021
- CADL 2021
- Fundamental
- Price
- EWCZ $5.24
- CADL $6.28
- Analyst Decision
- EWCZ Buy
- CADL Strong Buy
- Analyst Count
- EWCZ 7
- CADL 5
- Target Price
- EWCZ $5.86
- CADL $21.40
- AVG Volume (30 Days)
- EWCZ 571.2K
- CADL 1.0M
- Earning Date
- EWCZ 08-13-2025
- CADL 08-12-2025
- Dividend Yield
- EWCZ N/A
- CADL N/A
- EPS Growth
- EWCZ N/A
- CADL N/A
- EPS
- EWCZ 0.21
- CADL N/A
- Revenue
- EWCZ $216,469,000.00
- CADL N/A
- Revenue This Year
- EWCZ N/A
- CADL N/A
- Revenue Next Year
- EWCZ $2.17
- CADL N/A
- P/E Ratio
- EWCZ $26.04
- CADL N/A
- Revenue Growth
- EWCZ N/A
- CADL N/A
- 52 Week Low
- EWCZ $2.72
- CADL $3.79
- 52 Week High
- EWCZ $10.39
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- EWCZ 47.40
- CADL 58.86
- Support Level
- EWCZ $5.44
- CADL $4.86
- Resistance Level
- EWCZ $5.84
- CADL $6.42
- Average True Range (ATR)
- EWCZ 0.24
- CADL 0.34
- MACD
- EWCZ -0.07
- CADL 0.13
- Stochastic Oscillator
- EWCZ 6.87
- CADL 68.56
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.